Sinovac Biotech (SVA) Stock Statistics & Valuation Metrics

Sinovac Biotech has a market cap or net worth of $460.27M. The enterprise value is -$506.21M.

Sinovac Biotech has 71,860,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sinovac Biotech’s return on equity (ROE) is -0.01 and return on invested capital (ROIC) is -3.02%.

The current PE Ratio of Sinovac Biotech is ―. Sinovac Biotech’s PEG ratio is 0.00.

In the last 12 months, Sinovac Biotech had revenue of 386.01M and earned -59.68M in profits. Earnings per share was -0.83.

In the last 12 months, operating cash flow was 106.02M and capital expenditures -145.69M, giving a free cash flow of -39.67M billion.

Sinovac Biotech pays an annual dividend of $55, resulting in a dividend yield of 0%

Sinovac Biotech upcoming earnings date is Dec 17, 2026, TBA (Confirmed).

Sinovac Biotech as a current ratio of 4.59, with Debt / Equity ratio of 11.42%

In the past 12 months, Sinovac Biotech has paid -63.27M in taxes.

Sinovac Biotech EV to EBITDA ratio is 0.98, with an EV/FCF ratio of 0.33.

Sinovac Biotech has $11.22B in cash and marketable securities with $298.98M in debt, giving a net cash position of $10.92B billion.

Gross margin is 67.87%, with operating margin of -75.47%, and net profit margin of -15.46%.

The average price target for Sinovac Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―